Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...
HI-Bio’s $95 Million Series B Financing Round
BlueRock Therapeutics and bit.bio’s Collaboration and Option Agreement
Goodwin advised bit.bio on the agreement. BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, and bit.bio announced a collaboration and option agreement for...
HIBio’s License Agreements with MorphoSys AG
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
Senti Biosciences’ Business Combination with Dynamics Special Purpose Corp.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...